Shannon C. Dixon

1.0k total citations
18 papers, 844 citations indexed

About

Shannon C. Dixon is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shannon C. Dixon has authored 18 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Shannon C. Dixon's work include Prostate Cancer Treatment and Research (6 papers), Angiogenesis and VEGF in Cancer (5 papers) and Cancer-related Molecular Pathways (4 papers). Shannon C. Dixon is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Angiogenesis and VEGF in Cancer (5 papers) and Cancer-related Molecular Pathways (4 papers). Shannon C. Dixon collaborates with scholars based in United States, Spain and Italy. Shannon C. Dixon's co-authors include William D. Figg, Kenneth S. Bauer, William D. Figg, Erwin A. Kruger, Mikhail V. Blagosklonny, Eric J. Small, David Reese, Kevin Knopf, Richard M. Lush and Markus Borner and has published in prestigious journals such as Nature Biotechnology, Biochemical and Biophysical Research Communications and Pharmacological Reviews.

In The Last Decade

Shannon C. Dixon

18 papers receiving 802 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shannon C. Dixon United States 14 452 222 216 188 152 18 844
Steven L. Abrams United States 8 711 1.6× 123 0.6× 340 1.6× 107 0.6× 180 1.2× 9 1.0k
John W. Madsen United States 10 469 1.0× 105 0.5× 89 0.4× 79 0.4× 160 1.1× 11 791
Li-Yuan Bai Taiwan 17 466 1.0× 89 0.4× 150 0.7× 68 0.4× 99 0.7× 42 869
Michelle L. Kraus United States 7 466 1.0× 124 0.6× 447 2.1× 145 0.8× 129 0.8× 9 1.1k
Nicholas Davies United Kingdom 15 584 1.3× 68 0.3× 298 1.4× 86 0.5× 117 0.8× 25 1000
Wenwen Chien United States 20 822 1.8× 104 0.5× 250 1.2× 60 0.3× 212 1.4× 29 1.1k
Gennaro Colella Italy 16 800 1.8× 94 0.4× 439 2.0× 106 0.6× 154 1.0× 29 1.1k
Sarah Sarkar United States 12 486 1.1× 137 0.6× 356 1.6× 61 0.3× 268 1.8× 13 980
Pia Herrmann Germany 18 665 1.5× 104 0.5× 443 2.1× 152 0.8× 236 1.6× 31 1.1k
Gregory Dyson United States 20 577 1.3× 142 0.6× 304 1.4× 60 0.3× 326 2.1× 74 1.1k

Countries citing papers authored by Shannon C. Dixon

Since Specialization
Citations

This map shows the geographic impact of Shannon C. Dixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shannon C. Dixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shannon C. Dixon more than expected).

Fields of papers citing papers by Shannon C. Dixon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shannon C. Dixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shannon C. Dixon. The network helps show where Shannon C. Dixon may publish in the future.

Co-authorship network of co-authors of Shannon C. Dixon

This figure shows the co-authorship network connecting the top 25 collaborators of Shannon C. Dixon. A scholar is included among the top collaborators of Shannon C. Dixon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shannon C. Dixon. Shannon C. Dixon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Joshi, Shilpy, Johannes Freudenberg, Jagdeep Singh, et al.. (2025). Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis. Digestive and Liver Disease. 57. S27–S27. 2 indexed citations
2.
Schimmöller, Frauke, et al.. (2008). 97 POSTER Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647. European Journal of Cancer Supplements. 6(12). 33–33. 1 indexed citations
3.
Montgomery, Jeffrey S., Douglas K. Price, Shannon C. Dixon, et al.. (2002). The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer. Urologia Internationalis. 68(1). 16–23. 15 indexed citations
4.
Blagosklonny, Mikhail V., Shannon C. Dixon, Robert W. Robey, & William D. Figg. (2001). Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. International Journal of Oncology. 18(4). 697–704. 14 indexed citations
5.
Dixon, Shannon C., Kevin Knopf, & William D. Figg. (2001). The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents. Pharmacological Reviews. 53(1). 73–91. 48 indexed citations
6.
Bauer, Kenneth S., et al.. (2000). Carboxyamido-triazole Inhibits Angiogenesis by Blocking the Calcium-Mediated Nitric-Oxide Synthase-Vascular Endothelial Growth Factor Pathway. Journal of Pharmacology and Experimental Therapeutics. 292(1). 31–37. 49 indexed citations
7.
Kruger, Erwin A., Paul H. Duray, Maria Tsokos, et al.. (2000). Endostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis Assay. Biochemical and Biophysical Research Communications. 268(1). 183–191. 82 indexed citations
8.
Blagosklonny, Mikhail V., Shannon C. Dixon, & William D. Figg. (2000). EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES. The Journal of Urology. 163(3). 1022–1026. 34 indexed citations
9.
Dixon, Shannon C., et al.. (1999). Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemotherapy and Pharmacology. 43(7). S78–S84. 26 indexed citations
10.
Horti, J, Shannon C. Dixon, C. Logothetis, et al.. (1999). Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. British Journal of Cancer. 79(9-10). 1588–1593. 23 indexed citations
11.
Small, Eric J., et al.. (1999). Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.. PubMed. 5(7). 1738–44. 119 indexed citations
12.
Dixon, Shannon C., et al.. (1999). The androgen receptor: genetic considerations in the development and treatment of prostate cancer. Journal of Molecular Medicine. 77(5). 419–426. 33 indexed citations
13.
Dixon, Shannon C., et al.. (1998). Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nature Biotechnology. 16(1). 91–94. 35 indexed citations
14.
Dixon, Shannon C., et al.. (1998). Apoptosis: a novel therapeutic tool?. Expert Opinion on Investigational Drugs. 7(6). 889–904. 4 indexed citations
15.
Kruger, Erwin A., Mikhail V. Blagosklonny, Shannon C. Dixon, & William D. Figg. (1998). UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response. PubMed. 18(4). 209–218. 29 indexed citations
16.
Bauer, Kenneth S., Shannon C. Dixon, & William D. Figg. (1998). Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent. Biochemical Pharmacology. 55(11). 1827–1834. 246 indexed citations
17.
Dixon, Shannon C., et al.. (1997). Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target. Annals of Pharmacotherapy. 31(1). 76–82. 71 indexed citations
18.
Dixon, Shannon C., et al.. (1997). In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Cancer Letters. 113(1-2). 111–116. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven L. Abrams Breakdown of academic impact, for papers by John W. Madsen Breakdown of academic impact, for papers by Li-Yuan Bai Breakdown of academic impact, for papers by Michelle L. Kraus Breakdown of academic impact, for papers by Nicholas Davies Breakdown of academic impact, for papers by Wenwen Chien Breakdown of academic impact, for papers by Gennaro Colella Breakdown of academic impact, for papers by Sarah Sarkar Breakdown of academic impact, for papers by Pia Herrmann Breakdown of academic impact, for papers by Gregory Dyson
Rankless by CCL
2026